We analyzed 83 breast cancer patients: 35 had HR+/HER2- tumors, 13 HR+/HER2+ tumors, 19 HR-/HER2+ tumors, and 16 had TN tumors (Table 1). Here, ERBB2 is linked to breast cancer.